Jensen, Gorm Boje by unknown
Syddansk Universitet
Rare and low-frequency coding variants alter human adult height
Marouli, Eirini; Graff, Mariaelisa; Medina-Gómez, Carolina; Lo, Ken Sin; Wood, Andrew R;
Kjaer, Troels R; Fine, Rebecca S; Lu, Yingchang; Schurmann, Claudia; Highland, Heather M;
Rüeger, Sina; Thorleifsson, Gudmar; Justice, Anne E; Lamparter, David; Stirrups, Kathleen E;
Turcot, Valérie; Young, Kristin L; Winkler, Thomas W; Esko, Tonu; Karaderi, Tugce; Locke,
Adam E; Masca, Nicholas G D; Ng, Maggie C Y; Mudgal, Poorva; Rivas, Manuel A;
Vedantam, Sailaja; Mahajan, Anubha; Guo, Xiuqing; Abecasis, Goncalo R; Aben, Katja K;
Adair, Linda S; Alam, Dewan S; Albrecht, Eva; Allin, Kristine Højgaard; Allison, Matthew A;
Amouyel, Philippe; Appel, Emil Vincent Rosenbaum; Arveiler, Dominique; Asselbergs, Folkert
W; Auer, Paul L; Balkau, Beverley; Banas, Bernhard; Bang, Lia E; Benn, Marianne;
Bergmann, Sven; Brandslund, Ivan; Christensen, Cramer; Hansen, Torben; Jensen, Gorm
Boje ; Jørgensen, Marit Eika; EPIC-InterAct Consortium
Published in:
Nature
DOI:
10.1038/nature21039
Publication date:
2017
Document version
Peer reviewed version
Citation for pulished version (APA):
Marouli, E., Graff, M., Medina-Gómez, C., Lo, K. S., Wood, A. R., Kjaer, T. R., ... EPIC-InterAct Consortium
(2017). Rare and low-frequency coding variants alter human adult height. Nature, 542(7640), 186-190. DOI:
10.1038/nature21039
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Rare and low-frequency coding variants alter human adult height
A full list of authors and affiliations appears at the end of the article.
Summary
Height is a highly heritable, classic polygenic trait with ∼700 common associated variants 
identified so far through genome-wide association studies. Here, we report 83 height-associated 
coding variants with lower minor allele frequencies (range of 0.1-4.8%) and effects of up to 2 cm/
allele (e.g. in IHH, STC2, AR and CRISPLD2), >10 times the average effect of common variants. 
In functional follow-up studies, rare height-increasing alleles of STC2 (+1-2 cm/allele) 
compromised proteolytic inhibition of PAPP-A and increased cleavage of IGFBP-4 in vitro, 
resulting in higher bioavailability of insulin-like growth factors. These 83 height-associated 
variants overlap genes mutated in monogenic growth disorders and highlight new biological 
candidates (e.g. ADAMTS3, IL11RA, NOX4) and pathways (e.g. proteoglycan/
glycosaminoglycan synthesis) involved in growth. Our results demonstrate that sufficiently large 
sample sizes can uncover rare and low-frequency variants of moderate to large effect associated 
with polygenic human phenotypes, and that these variants implicate relevant genes and pathways.
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Introduction
Human height is a highly heritable, polygenic trait1,2. The contribution of common DNA 
sequence variation to inter-individual differences in adult height has been systematically 
evaluated through genome-wide association studies (GWAS). This approach has thus far 
identified 697 independent variants located within 423 loci that together explain ∼20% of 
the heritability of height3. As is typical of complex traits and diseases, most of the height 
alleles discovered so far are common (minor allele frequency (MAF) >5%) and are mainly 
located outside coding regions, complicating the identification of the relevant genes or 
functional variants. Identifying coding variants associated with a complex trait in new or 
known loci has the potential to pinpoint causal genes. Furthermore, the extent to which rare 
(MAF <1%) and low-frequency (1%< MAF ≤ 5%) coding variants also influence complex 
traits and diseases remains an open question. Many recent DNA sequencing studies have 
identified only few such variants4-8, but this limited success could be due to their modest 
sample size9. Some studies have suggested that common sequence variants may explain the 
majority of the heritable variation in adult height10, making it timely to assess whether and 
to what extent rare and low-frequency coding variation contributes to the genetic landscape 
of this model polygenic trait.
In this study, we used an ExomeChip11 to test the association between 241,453 variants 
(83% coding with MAF ≤5%) and adult height variation in 711,428 individuals (discovery 
and validation sample sizes were 458,927 and 252,501, respectively). The ExomeChip is a 
genotyping array designed to query in very large sample sizes coding variants identified by 
whole-exome DNA sequencing of ∼12,000 participants. The main goals of our project were 
to determine whether rare and low-frequency coding variants influence the architecture of a 
model complex human trait, such as adult height, and to discover and characterize new genes 
and biological pathways implicated in human growth.
Results
32 rare and 51 low-frequency coding variants associated with adult height
We conducted single-variant meta-analyses in a discovery sample of 458,927 individuals, of 
whom 381,625 were of European ancestry. We validated our association results in an 
independent set of 252,501 participants. We first performed standard single-variant 
association analyses; technical details of the discovery and validation steps are in Methods 
(Extended Data Figs 1-3, Supplementary Tables 1-11). In total, we found 606 independent 
ExomeChip variants at array-wide significance (P<2×10-7), including 252 non-synonymous 
or splice site variants (Methods and Supplementary Table 11). Focusing on non-synonymous 
or splice site variants with MAF <5%, our single-variant analyses identified 32 rare and 51 
low-frequency height-associated variants (Extended Data Tables 1-2). To date, these 83 
height variants (MAF range 0.1-4.8%) represent the largest set of validated rare and low-
frequency coding variants associated with any complex human trait or disease. Among these 
83 variants, there are 81 missense, one nonsense (in CCND3), and one essential acceptor 
splice site (in ARMC5) variants.
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We observed a strong inverse relationship between MAF and effect size (Fig. 1). Although 
power limits our capacity to find rare variants of small effects, we know that common 
variants with effect sizes comparable to the largest seen in our study would have been easily 
discovered by prior GWAS, but were not detected. Our results agree with a model based on 
accumulating theoretical and empirical evidences that suggest that variants with strong 
phenotypic effects are more likely to be deleterious, and therefore rarer12,13. The largest 
effect sizes were observed for four rare missense variants, located in the androgen receptor 
gene AR (rs137852591, MAF=0.21%, Pcombined=2.7×10-14), in CRISPLD2 (rs148934412, 
MAF=0.08%, Pcombined=2.4×10-20), in IHH (rs142036701, MAF=0.08%, 
Pcombined=1.9×10-23), and in STC2 (rs148833559, MAF=0.1%, Pcombined=1.2×10-30). 
Carriers of the rare STC2 missense variant are ∼2.1 cm taller than non-carriers, whereas 
carriers of the remaining three variants (or hemizygous men that carry the X-linked AR-
rs137852591 rare allele) are ∼2 cm shorter than non-carriers. In comparison, the mean effect 
size of common height alleles is ten times smaller in the same dataset. Across all 83 rare and 
low-frequency non-synonymous variants, the minor alleles were evenly distributed between 
height-increasing and -decreasing effects (48% vs. 52%, respectively) (Fig. 1 and Extended 
Data Tables 1-2).
Coding variants in new and known height loci, and heritability explained
Many of the height-associated variants in this ExomeChip effort are located near common 
variants previously associated with height. Of the 83 rare and low-frequency non-
synonymous variants, two low-frequency missense variants were previously identified (in 
CYTL1 and IL11)3,14 and 47 fell within 1 Mb of a known height signal; the remaining 34 
define new loci. We used conditional analysis in the UK Biobank dataset and confirmed that 
38 of these 47 variants were independent from the previously described height SNPs 
(Supplementary Table 12). We validated the UK Biobank conditional results using an 
orthogonal imputation-based methodology implemented in the full discovery set (Extended 
Data Fig. 4 and Supplementary Table 12). In addition, we found a further 85 common 
variants and one low-frequency synonymous variant (in ACHE) that define novel loci 
(Supplementary Table 12). Thus, our study identified a total of 120 new height loci 
(Supplementary Table 11).
We used the UK Biobank dataset to estimate the contribution of the new height variants to 
heritability, which is h2∼80% for adult height2. In combination, the 83 rare and low-
frequency variants explained 1.7% of the heritability of height. The newly identified novel 
common variants accounted for another 2.4%, and all independent variants, known and 
novel together explained 27.4% of heritability. By comparison, the 697 known height SNPs 
explain 23.3% of height heritability in the same dataset (vs. 4.1% by the new height variants 
identified in this ExomeChip study). We observed a modest positive association between 
MAF and heritability explained per variant (P=0.012, Extended Data Fig. 5), with each 
common variant explaining slightly more heritability than rare or low-frequency variants 
(0.036% vs. 0.026%, Extended Data Fig. 5).
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Gene-based association results
To increase power to find rare or low-frequency coding variants associated with height, we 
performed gene-based analyses (Methods and Supplementary Tables 13-15). After 
accounting for gene-based signals explained by a single variant driving the association 
statistics, we identified ten genes with P<5×10-7 that harbor more than one coding variant 
independently associated with height variation (Supplementary Tables 16-17). These gene-
based results remained significant after conditioning on genotypes at nearby common 
height-associated variants present on the ExomeChip (Table 1). Using the same gene-based 
tests in an independent dataset of 59,804 individuals genotyped on the same exome array, we 
replicated three genes at P<0.05 (Table 1). Further evidence for replication in these genes 
was seen at the level of single variants (Supplementary Table 18). From the gene-based 
results, three genes – CSAD, NOX4, and UGGT2 – fell outside of the loci found by single-
variant analyses and are implicated in human height for the first time.
Coding variants implicate biological pathways in human skeletal growth
Prior pathway analyses of height loci identified by GWAS have highlighted gene sets related 
to both general biological processes (such as chromatin modification and regulation of 
embryonic size) and more skeletal growth-specific pathways (chondrocyte biology, 
extracellular matrix (ECM), and skeletal development)3. We used two different methods, 
DEPICT15 and PASCAL16 (Methods), to perform pathway analyses using the ExomeChip 
results to test whether coding variants could either independently confirm the relevance of 
these previously highlighted pathways (and further implicate specific genes in these 
pathways), or identify new pathways. To compare the pathways emerging from coding and 
non-coding variation, we applied DEPICT separately on (1) exome array-wide associated 
coding variants independent of known GWAS signals and (2) non-coding GWAS loci, 
excluding all novel height-associated genes implicated by coding variants. We identified a 
total of 496 and 1,623 enriched gene sets, respectively, at a false discovery rate (FDR) <1% 
(Supplementary Tables 19-20); similar analyses with PASCAL yielded 362 and 278 enriched 
gene sets (Supplementary Tables 21-22). Comparison of the results revealed a high degree of 
shared biology for coding and non-coding variants (for DEPICT, gene set P-values 
compared between coding and non-coding results had Pearson's r = 0.583, P<2.2×10-16; for 
PASCAL, Pearson's r=0.605, P<2.2×10-16). However, some pathways showed stronger 
enrichment with either coding or non-coding genetic variation. In general, coding variants 
more strongly implicated pathways specific to skeletal growth (such as ECM and bone 
growth), while GWAS signals highlighted more global biological processes (such as 
transcription factor binding and embryonic size/lethality) (Extended Data Fig. 6). The two 
significant gene sets identified by DEPICT and PASCAL that uniquely implicated coding 
variants were “BCAN protein protein interaction subnetwork” and “proteoglycan binding.” 
Both of these pathways relate to the biology of proteoglycans, which are proteins (such as 
aggrecan) that contain glycosaminoglycans (such as chrondroitin sulfate) and that have well-
established connections to skeletal growth17.
We also examined which height-associated genes identified by ExomeChip analyses were 
driving enrichment of pathways such as proteoglycan binding. Using unsupervised 
clustering analysis, we observed that a cluster of 15 height-associated genes is strongly 
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implicated in a group of correlated pathways that include biology related to proteoglycans/
glycosaminoglycans (Fig. 2 and Extended Data Fig. 7). Seven of these 15 genes overlap a 
previously curated list of 277 genes annotated in OMIM as causing skeletal growth 
disorders3; genes in this small cluster are enriched for OMIM annotations relative to genes 
outside the cluster (odds ratio=27.6, Fisher's exact P=1.1×10-5). As such, the remaining 
genes in this cluster may be strong candidates for harboring variants that cause Mendelian 
growth disorders. Within this group are genes that are largely uncharacterized (SUSD5), 
have relevant biochemical functions (GLT8D2, a glycosyl transferase studied mostly in the 
context of the liver18; LOXL4, a lysyl oxidase expressed in cartilage19), modulate pathways 
known to affect skeletal growth (FIBIN, SFRP4)20,21 or lead to increased body length when 
knocked out in mice (SFRP4)22.
Functional characterization of rare STC2 variants
To begin exploring whether the identified rare coding variants affect protein function, we 
performed in vitro functional analyses of two rare coding variants in a particularly 
compelling and novel candidate gene, STC2. Over-expression of STC2 diminishes growth in 
mice by covalent binding and inhibition of the proteinase PAPP-A, which specifically 
cleaves IGF binding protein-4 (IGFBP-4), leading to reduced levels of bioactive insulin-like 
growth factors (Fig. 3A)23. Although there was no prior genetic evidence implicating STC2 
variation in human growth, the PAPPA and IGFBP4 genes were both implicated in height 
GWAS3, and rare mutations in PAPPA2 cause severe short stature24, emphasizing the likely 
relevance of this pathway in humans. The two STC2 height-associated variants are 
rs148833559 (p.Arg44Leu, MAF=0.096%, Pdiscovery=5.7×10-15) and rs146441603 
(p.Met86Ile, MAF=0.14%, Pdiscovery=2.1×10-5). These rare alleles increase height by 1.9 
and 0.9 cm, respectively, suggesting that they both partially impair STC2 activity. In 
functional studies, STC2 with these amino acid substitutions were expressed at similar levels 
to wild-type, but showed clear, partial defects in binding to PAPP-A and in inhibition of 
PAPP-A-mediated cleavage of IGFBP-4 (Fig. 3B-D). Thus, the genetic analysis successfully 
identified rare coding alleles that have demonstrable and predicted functional consequences, 
strongly confirming the role of these variants and the STC2 gene in human growth.
Pleiotropic effects
Previous GWAS studies have reported pleiotropic or secondary effects on other phenotypes 
for many common variants associated with adult height3,25. Using association results from 
17 human complex phenotypes for which well-powered meta-analysis results were available, 
we explored if rare and low-frequency height variants are also pleiotropic. We found one 
rare and five low-frequency missense variants associated with at least one of the other 
investigated traits at array-wide significance (P<2×10-7)(Extended Data Fig. 8 and 
Supplementary Table 23). The minor alleles at rs77542162 (ABCA6, MAF=1.7%) and 
rs28929474 (SERPINA1, MAF=1.8%) were associated with increased height and increased 
levels of LDL-cholesterol (LDL-C) and total cholesterol (TC), whereas the minor allele at 
rs3208856 in CBLC (MAF=3.4%) was associated with increased height, HDL-cholesterol 
(HDL-C) and triglyceride (TG), but lower LDL-C and TC levels. The minor allele at 
rs141845046 (ZBTB7B, MAF=2.8%) was associated with both increased height and body 
mass index (BMI). The minor alleles at the other two missense variants associated with 
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shorter stature, rs201226914 in PIEZO1 (MAF=0.2%) and rs35658696 in PAM 
(MAF=4.8%), were associated with decreased glycated haemoglobin (HbA1c) and increased 
type 2 diabetes (T2D) risk, respectively.
Discussion
We undertook an association study of nearly 200,000 coding variants in 711,428 individuals, 
and identified 32 rare and 51 low-frequency coding variants associated with adult height. 
Furthermore, gene-based testing discovered 10 genes that harbor several additional rare/low-
frequency variants associated with height, including three genes (CSAD, NOX4, UGGT2) in 
loci not previously implicated in height. Given the design of the ExomeChip, which did not 
consider variants with MAF <0.004% (or one allele in ∼12,000 participants), our gene-based 
association results do not rule out the possibility that additional genes with such rarer coding 
variants also contribute to height variation; deep DNA sequencing in very large sample sizes 
will be required to address this question. In total, our results highlight 89 genes (10 from 
gene-based testing and 79 from single-variant analyses (four genes have 2 independent 
coding variants)) that are likely to modulate human growth, and 24 alleles segregating in the 
general population that affect height by more than 1 cm (Extended Data Tables 1-2 and 
Table 1). The rare and low-frequency coding variants explain 1.7% of the heritable variation 
in adult height. When considering all rare, low-frequency, and common height-associated 
variants validated in this study, we can now explain 27.4% of the heritability.
Our analyses revealed many coding variants in genes mutated in monogenic skeletal growth 
disorders, confirming the presence of allelic series (from familial penetrant mutations to 
mild effect common variants) in the same genes for related growth phenotypes in humans. 
We used gene set enrichment-type analyses to demonstrate the functional connectivity 
between the genes that harbor coding height variants, highlighting known as well as novel 
biological pathways that regulate height in humans (Fig. 2, Extended Data Fig. 7 and 
Supplementary Tables 19-22), and newly implicating genes such as SUSD5, GLT8D2, 
LOXL4, FIBIN, and SFRP4 that have not been previously connected with skeletal growth. 
Additional interesting height candidate genes include NOX4, ADAMTS3 and ADAMTS6, 
PTH1R, and IL11RA (Extended Data Tables 1-2, Supplementary Tables 17 and 24). NOX4, 
identified through gene-based testing, encodes NADPH oxidase 4, an enzyme that produces 
reactive oxygen species, a biological pathway not previously implicated in human growth. 
Nox4-/- mice display higher bone density and reduced numbers of osteoclasts, a cell type 
essential for bone repair, maintenance, and remodelling12. We also found rare coding 
variants in ADAMTS3 and ADAMTS6, genes that encode metalloproteinases that belong to 
the same family than several other human growth syndromic genes (e.g. ADAMTS2, 
ADAMTS10, ADAMTSL2). Moreover, we discovered a rare missense variant in PTH1R 
that encodes a receptor of the parathyroid hormone (PTH): PTH-PTH1R signaling is 
important for bone resorption and mutations in PTH1R cause chondrodysplasia in humans26. 
Finally, we replicated the association between a low-frequency missense variant in the 
cytokine gene IL11, but also found a new low-frequency missense variant in its receptor 
gene IL11RA. The IL11-IL11RA axis has been shown to play an important role in bone 
formation in the mouse27,28. Thus, our data confirm the relevance of this signaling cascade 
in human growth as well.
Marouli et al. Page 6
Nature. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Overall, our findings provide strong evidence that rare and low-frequency coding variants 
contribute to the genetic architecture of height, a model complex human trait. This 
conclusion has strong implications for the prediction of complex human phenotypes in the 
context of precision medicine initiatives. Indeed, although rare, large effect size variants 
might not explain most of the heritable disease risk at the population level, they are 
important to predict the risk to develop disease for individuals that carry them. Our findings 
also seem to contrast sharply with results from the recent large-scale T2D association study, 
which found only six variants with MAF <5% (ref. 29). This apparent difference could 
simply be explained by the large difference in sample sizes between the two studies 
(711,428 for height vs. 127,145 for T2D). When we consider the fraction of associated 
variants with MAF<5% among all confirmed variants for height and T2D, we find that it is 
similar (9.7% for height vs. 7.1% for T2D). This supports the strong probability that rarer 
T2D alleles and more generally, rarer alleles for other polygenic diseases and traits, will be 
uncovered as sample sizes continue to increase.
Methods
Study design & participants
The discovery cohort consisted of 147 studies comprising 458,927 adult individuals of the 
following ancestries: 1) European descent (N=381,625), 2) African (N=27,494), 3) South 
Asian (N=29,591), 4) East Asian (N=8,767); 5) Hispanic (N=10,776) and 6) Saudi (N=695). 
All participating institutions and coordinating centers approved this project, and informed 
consent was obtained from all subjects. Discovery meta-analysis was carried out in each 
ancestry group (except the Saudi) separately as well as in the All group. Validation was 
undertaken in individuals of European ancestry only (Supplementary Tables 1-3). 
Conditional analyses were undertaken only in the European descent group (106 studies, 
N=381,625).
Phenotype
Height (in centimeters) was corrected for age and the genomic principal components 
(derived from GWAS data, the variants with MAF >1% on ExomeChip, or ancestry 
informative markers available on the ExomeChip), as well as any additional study-specific 
covariates (e.g. recruiting center), in a linear regression separately by sex, whereas for 
family-based studies sex was included as a covariate in model. For studies with non-related 
individuals, residuals were calculated the model. Additionally, residuals for case/control 
studies were calculated separately. Finally, residuals were subject to inverse normal 
transformation.
Genotype calling
The majority of studies followed a standardized protocol and performed genotype calling 
using the designated manufacturer software, which was then followed by zCall31. For 10 
studies participating in the Cohorts for Heart and Aging Research in Genomic Epidemiology 
(CHARGE) Consortium, the raw intensity data for the samples from seven genotyping 
centers were assembled into a single project for joint calling11. Study-specific quality 
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control (QC) measures of the genotyped variants was implemented before association 
analysis (Supplementary Tables 1-2).
Study-level statistical analyses
Individual cohorts were analyzed separately for each ancestry population, with either 
RAREMETALWORKER (http://genome.sph.umich.edu/wiki/RAREMETALWORKER) or 
RVTEST (http://zhanxw.github.io/rvtests/), to associate inverse normal transformed height 
data with genotype data taking potential cryptic relatedness (kinship matrix) into account in 
a linear mixed model. These software are designed to perform score-statistics based rare-
variant association analysis, can accommodate both unrelated and related individuals, and 
provide single-variant results and variance-covariance matrix. The covariance matrix 
captures linkage disequilibrium (LD) relationships between markers within 1 Mb, which is 
used for gene-level meta-analyses and conditional analyses32. Single-variant analyses were 
performed for both additive and recessive models (for the alternate allele).
Centralized quality-control
The individual study data were investigated for potential existence of ancestry population 
outliers based on 1000 Genome Project phase 1 ancestry reference populations. A 
centralized QC procedure implemented in EasyQC33 was applied to individual study 
association summary statistics to identify outlying studies: (1) assessment of possible 
problems in height transformation,(2) comparison of allele frequency alignment against 
1000 Genomes Project phase 1 reference data to pinpoint any potential strand issues, and (3) 
examination of quantile-quantile (QQ) plots per study to identify any problems arising from 
population stratification, cryptic relatedness and genotype biases. We excluded variants if 
they had call rate <95%, Hardy-Weinberg equilibrium P<1×10-7, or large allele frequency 
deviations from reference populations (>0.6 for all ancestry analyses and >0.3 for ancestry-
specific population analyses). We also excluded from downstream analyses markers not 
present on the Illumina ExomeChip array 1.0, variants on the Y-chromosome or the 
mitochondrial genome, indels, multiallelic variants, and problematic variants based on the 
Blat-based sequence alignment analyses. Meta-analyses were carried out in parallel by two 
different analysts at two sites.
Single-variant meta-analyses
Discovery analyses—We conducted single-variant meta-analyses in a discovery sample 
of 458,927 individuals of different ancestries using both additive and recessive genetic 
models (Extended Data Fig. 1 and Supplementary Tables 1-4). Significance for single-
variant analyses was defined at array-wide level (P<2×10-7, Bonferroni correction for 
250,000 variants). The combined additive analyses identified 1,455 unique variants that 
reached array-wide significance (P<2×10-7), including 578 non-synonymous and splice site 
variants (Supplementary Tables 5-7). Under the additive model, we observed a high genomic 
inflation of the test statistics (e.g. λGC of 2.7 in European-ancestry studies for common 
markers, Extended Data Fig. 2 and Supplementary Table 8), although validation results (see 
below) and additional sensitivity analyses (see below) suggested that it is consistent with 
polygenic inheritance as opposed to population stratification, cryptic relatedness, or 
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technical artifacts (Extended Data Fig. 2). The majority of these 1,455 association signals 
(1,241; 85.3%) were found in the European-ancestry meta-analysis (85.5% of the discovery 
sample size) (Extended Data Fig. 2). Nevertheless, we discovered eight associations within 
five loci in our all-ancestry analyses that are driven by African studies (including one 
missense variant in the growth hormone gene GH1 (rs151263636), Extended Data Fig. 3), 
three height variants found only in African studies, and one rare missense marker associated 
with height in South Asians only (Supplementary Table 7).
Genomic inflation and confounding—We observed a marked genomic inflation of the 
test statistics even after adequate control for population stratification (linear mixed model) 
arising mainly from common markers; λGC in European-ancestry was 1.2 and 2.7 for all and 
common markers, respectively (Extended Data Fig. 2 and Supplementary Table 8). Such 
inflation is expected for a highly polygenic trait like height, and is consistent with our very 
large sample size3,34. To confirm this, we applied the recently developed linkage 
disequilibrium (LD) score regression method to our height ExomeChip results30, with the 
caveats that the method was developed (and tested) with >200,000 common markers 
available. We restricted our analyses to 15,848 common variants (MAF ≥5%) from the 
European-ancestry meta-analysis, and matched them to pre-computed LD scores for the 
European reference dataset30. The intercept of the regression of the χ2 statistics from the 
height meta-analysis on the LD score estimate the inflation in the mean χ2 due to 
confounding bias, such as cryptic relatedness or population stratification. The intercept was 
1.4 (standard error=0.07), which is small when compared to the λGC of 2.7. Furthermore, 
we also confirmed that the LD score regression intercept is estimated upward because of the 
small number of variants on the ExomeChip and the selection criteria for these variants (i.e. 
known GWAS hits). The ratio statistic of (intercept -1) / (mean χ2 -1) is 0.067 (standard 
error=0.012), well within the normal range30, suggesting that most of the inflation (∼93%) 
observed in the height association statistics is due to polygenic effects (Extended Data Fig. 
2).
Furthermore, to exclude the possibility that some of the observed associations between 
height and rare/low-frequency variants could be due to allele calling problems in the smaller 
studies, we performed a sensitivity meta-analysis with primarily Europe-ancestry studies 
totaling >5,000 participants. We found very concordant effect sizes, suggesting that smaller 
studies do not bias our results (Extended Data Fig. 2).
Conditional analyses—The RAREMETAL R-package35 and the GCTA v1.2436 software 
were used to identify independent height association signals across the European descent 
meta-analysis results. RAREMETAL performs conditional analyses by using covariance 
matrices in order to distinguish true signals from those driven by LD at adjacent known 
variants. First, we identified the lead variants (P<2×10-7) based on a 1 Mb window centered 
on the most significantly associated variant and performed LD pruning (r2<0.3) to avoid 
downstream problems in the conditional analyses due to co-linearity. We then conditioned 
on the LD-pruned set of lead variants in RAREMETAL and kept new lead signals at 
P<2×10-7. The process was repeated until no additional signal emerged below the pre-
specified P-value threshold. The use of a 1 Mb window in RAREMETAL can obscure 
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dependence between conditional signals in adjacent intervals in regions of extended LD. To 
detect such instances, we performed joint analyses using GCTA with the ARIC and UK 
ExomeChip reference panels, both of which comprise >10,000 individuals of European 
descent. With the exception of a handful of variants in a few genomic regions with extended 
LD (e.g. the HLA region on chromosome 6), the two software identified the same 
independent signals (at P<2×10-7).
To discover new height variants, we conditioned the height variants found in our ExomeChip 
study on the previously published GWAS height variants3 using the first release of the UK 
Biobank imputed dataset and regression methodology implemented in BOLT-LMM37. 
Because of the difference between the sample size of our discovery set (N=458,927) and the 
UK Biobank (first release, N=120,084), we applied a threshold of Pconditional<0.05 to declare 
a height variant as independent in this analysis. We also explored an alternative approach 
based on approximate conditional analysis36. This latter method (SSimp) relies on summary 
statistics available from the same cohort, thus we first imputed summary statistics38 for 
exome variants, using summary statistics from the Wood et al. 2014 study3. Conversely, we 
imputed the top variants from the Wood et al. 2014 study using the summary statistics from 
the ExomeChip. Subsequently, we calculated effect sizes for each exome variant conditioned 
on the Wood et al. 2014 top variants in two ways. First, we conditioned the imputed 
summary statistics of the exome variant on the summary statistics of the Wood et al. 2014 
top variants that fell within 5 Mb of the target ExomeChip variant. Second, we conditioned 
the summary statistics of the ExomeChip variant on the imputed summary statistics of the 
Wood et al. 2014 hits. We then selected the option that yielded a higher imputation quality. 
For poorly tagged variants (r2̂ < 0.8), we simply used up-sampled HapMap summary 
statistics for the approximate conditional analysis. Pairwise SNP-by-SNP correlations were 
estimated from the UK10K data (TwinsUK39 and ALSPAC40 studies, N=3,781).
Validation of the single-variant discovery results—Several studies, totaling 252,501 
independent individuals of European ancestry, became available after the completion of the 
discovery analyses, and were thus used for validation of our experiment. We validated the 
single-variant association results in eight studies, totaling 59,804 participants, genotyped on 
the Exomechip using RAREMETAL32. We sought additional evidence for association for 
the top signals in two independent studies in the UK (UK Biobank) and Iceland (deCODE), 
comprising 120,084 and 72,613 individuals, respectively. We used the same QC and 
analytical methodology as described above. Genotyping and study descriptives are provided 
in Supplementary Tables 1-3. For the combined analysis, we used the inverse-variance 
weighted fixed effects meta-analysis method using METAL41. Significant associations were 
defined as those with a combined meta-analysis (discovery and validation) 
Pcombined<2×10-7.
We considered 81 variants with suggestive association in the discovery analyses 
(2×10-7<Pdiscovery≤2×10-6). Of those 81 variants, 55 reached significance after combining 
discovery and replication results based on Pcombined<2×10-7 (Supplementary Table 9). 
Furthermore, recessive modeling confirmed seven new independent markers with 
Pcombined<2×10-7 (Supplementary Table 10). One of these recessive signals is due to a rare 
X-linked variant in the AR gene (rs137852591, MAF=0.21%). Because of its frequency, we 
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only tested hemizygous men (we did not identify homozygous women for the minor allele) 
so we cannot distinguish between a true recessive mode of inheritance or a sex-specific 
effect for this variant. To test the independence and integrate all height markers from the 
discovery and validation phase, we used conditional analyses and GCTA “joint” modeling36 
in the combined discovery and validation set. This resulted in the identification of 606 
independent height variants, including 252 non-synonymous or splice site variants 
(Supplementary Table 11). If we only consider the initial set of lead SNPs with P<2×10-7, 
we identified 561 independent variants. Of these 561 variants (selected without the 
validation studies), 560 have concordant direction of effect between the discovery and 
validation studies, and 548 variants have a Pvalidation<0.05 (466 variants with 
Pvalidation<8.9×10-5, Bonferroni correction for 561 tests), suggesting a very low false 
discovery rate (Supplementary Table 11).
Gene-based association meta-analyses
For the gene-based analyses, we applied two different sets of criteria to select variants, based 
on coding variant annotation from five prediction algorithms (PolyPhen2 HumDiv and 
HumVar, LRT, Mutation Taster and SIFT)42. The mask labeled “broad” included variants 
with a MAF <0.05 that are nonsense, stop-loss, splice site, as well as missense variants that 
are annotated as damaging by at least one program mentioned above. The mask labeled 
“strict” included only variants with MAF <0.05 that are nonsense, stop-loss, splice site, as 
well as missense variants annotated as damaging by all five algorithms. We used two tests 
for gene-based testing, namely the SKAT43 and VT44 tests. Statistical significance for gene-
based tests was set at a Bonferroni-corrected threshold of P<5×10-7 (threshold for 25,000 
genes and four tests). The gene-based discovery results were validated (same test and 
variants, when possible) in the same eight studies genotyped on the ExomeChip (N=59,804 
participants) that were used for the validation of the single-variant results (see above, and 
Supplementary Tables 1-3). Gene-based conditional analyses were performed in 
RAREMETAL.
Pleiotropy analyses
We accessed ExomeChip data from GIANT (BMI, waist-hip ratio), GLGC (total cholesterol 
(TC), triglycerides (TG), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C)), IBPC 
(systolic and diastolic blood pressure), MAGIC (glycaemic traits), REPROGEN (age at 
menarche and menopause), and DIAGRAM (type 2 diabetes). For coronary artery disease, 
we accessed 1000 Genomes Project-imputed GWAS data released by 
CARDIoGRAMplusC4D45.
Pathway analyses
DEPICT is a computational framework that uses probabilistically-defined reconstituted gene 
sets to perform gene set enrichment and gene prioritization15. For a description about gene 
set reconstitution please refer to references 15 and 46. In brief, reconstitution was performed 
by extending pre-defined gene sets (such as Gene Ontology terms, canonical pathways, 
protein-protein interaction subnetworks and rodent phenotypes) with genes co-regulated 
with genes in these pre-defined gene set using large-scale microarray-based transcriptomics 
data. In order to adapt the gene set enrichment part of DEPICT for ExomeChip data, we 
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made two principal changes. First and foremost, because DEPICT for GWAS incorporates 
all genes within a given LD block around each index SNP, we modified DEPICT to take as 
input only the gene directly impacted by the coding SNP. Second, we adapted the way 
DEPICT adjust for confounders (such as gene length) by generating null ExomeChip 
association results using Swedish ExomeChip data (Malmö Diet and Cancer (MDC), All 
New Diabetics in Scania (ANDIS), and Scania Diabetes Registry (SDR) cohorts, N=11,899) 
and randomly assigning phenotypes from a normal distribution before conducting 
association analysis (see Supplementary Information). For the gene set enrichment analysis 
of the ExomeChip data, we used significant non-synonymous variants statistically 
independent of known GWAS hits (and that were present in the null ExomeChip data; see 
Supplementary Information for details). For gene set enrichment analysis of the GWAS data, 
we used all loci (1) with a non-coding index SNP and (2) that did not contain any of the 
novel ExomeChip genes. In visualizing the analysis, we used affinity propagation 
clustering47 to group the most similar reconstituted gene sets based on their gene 
memberships (see Supplementary Information). Within a “meta-gene set”, the best P-value 
of any member gene set was used as representative for comparison. DEPICT for ExomeChip 
was written using the Python programming language and the code can be found at https://
github.com/RebeccaFine/height-ec-depict.
We also applied the PASCAL pathway analysis tool16 to association summary statistics for 
all coding variants. In brief, the method derives gene-based scores (both SUM and MAX 
statistics) and subsequently tests for the over-representation of high gene scores in 
predefined biological pathways. We used standard pathway libraries from KEGG, 
REACTOME and BIOCARTA, and also added dichotomized (Z-score>3) reconstituted gene 
sets from DEPICT15. To accurately estimate SNP-by-SNP correlations even for rare 
variants, we used the UK10K data (TwinsUK39 and ALSPAC40 studies, N=3781). In order 
to separate the contribution of regulatory variants from the coding variants, we also applied 
PASCAL to association summary statistics of only regulatory variants (20 kb upstream, gene 
body excluded) from the Wood et al. study3. In this way, we could classify pathways driven 
principally by coding, regulatory or mixed signals.
STC2 functional experiments
Mutagenesis, cell culture and transfection—For the generation of STC2 mutants 
(R44L and M86I), wild-type STC2 cDNA contained in pcDNA3.1/Myc-His(-) 
(Invitrogen)23 was used as a template. Mutagenesis was carried out using Quickchange 
(Stratagene), and all constructs were verified by sequence analysis. Recombinant wild-type 
STC2 and variants were expressed in human embryonic kidney (HEK) 293T cells 
(293tsA1609neo, ATCC CRL-3216) maintained in high-glucose DMEM supplemented 10% 
fetal bovine serum, 2 mM glutamine, nonessential amino acids, and gentamicin. The cells 
are routinely tested for mycoplasma contamination. Cells (6×106) were plated onto 10 cm-
dishes and transfected 18 h later by calcium phosphate coprecipitation using 10 μg plasmid 
DNA. Media were harvested 48 h post transfection, cleared by centrifugation, and stored at 
-20°C until use. Protein concentrations (58-66 nM) were determined by TRIFMA using 
antibodies described previously23. PAPP-A was expressed stably in HEK293T cells as 
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previously reported48. Expressed levels of PAPP-A (27.5 nM) were determined by a 
commercial ELISA (AL-101, Ansh Labs, TX).
STC2 and PAPP-A complex formation—Culture supernatants containing wild-type 
STC2 or variants were adjusted to 58 nM, added an equal volume of culture supernatant 
containing PAPP-A corresponding to a 2.1-fold molar excess, and incubated at 37°C. 
Samples were taken at 1, 2, 4, 6, 8, 16, and 24 h and stored at -20°C.
Analysis of proteolytic activity—Specific proteolytic cleavage of 125I-labeled IGFBP-4 
is described in detail elsewhere49. Briefly, the PAPP-A:STC2 complex mixtures were diluted 
(1:190) to a concentration of 145 pM PAPP-A and mixed with preincubated 125I-IGFBP4 
(10 nM) and IGF-1 (100 nM) in 50 mM Tris-HCl, 100 mM NaCl, 1 mM CaCl2. Following 1 
h incubation at 37°C, reactions were terminated by the addition of SDS-PAGE sample buffer 
supplemented with 25 mM EDTA. Substrate and co-migrating cleavage products were 
separated by 12% nonreducing SDS-PAGE and visualized by autoradiography using a 
storage phosphor screen (GE Healthcare) and a Typhoon imaging system (GE Healthcare). 
Band intensities were quantified using ImageQuant TL 8.1 software (GE Healthcare).
Western blotting—STC2 and covalent complexes between STC2 and PAPP-A were 
blotted onto PVDF membranes (Millipore) following separation by 3-8% SDS-PAGE. The 
membranes were blocked with 2% Tween-20, and equilibrated in 50 mM Tris-HCl, 500 mM 
NaCl, 0.1% Tween-20, pH 9 (TST). For STC2, the membranes were incubated with goat 
polyclonal anti-STC2 (R&D systems, AF2830) at 0.5 μg/ml in TST supplemented with 2% 
skim milk for 1 h at 20°C. For PAPP-A:STC2 complexes, the membranes were incubated 
with rabbit polyclonal anti-PAPP-A50 at 0.63 μg/ml in TST supplemented with 2% skim 
milk for 16 h at 20°C. Membranes were washed with TST and subsequently incubated with 
polyclonal swine anti-rabbit IgG-HRP (DAKO, P0217) or polyclonal rabbit anti-goat IgG-
HRP (DAKO, P0449), respectively, diluted 1:2000 in TST supplemented with 2% skim milk 
for 1 h at 20°C. Following washing with TST, membranes were developed using enhanced 
chemiluminescence (ECL Prime, GE Healthcare). Images were captured using an 
ImageQuant LAS 4000 instrument (GE Healthcare).
Data Availability Statement
Summary genetic association results are available on the GIANT website: http://
portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium.
URLs
ClinVar, http://www.ncbi.nlm.nih.gov/clinvar/
DEPICT, http://www.broadinstitute.org/mpg/depict/
ExomeChip, http://genome.sph.umich.edu/wiki/Exome_Chip_Design
ExomeDEPICT, https://github.com/RebeccaFine/height-ec-depict
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OMIM, http://omim.org/
PASCAL, http://www2.unil.ch/cbg/index.php?title=Pascal
RAREMETALWORKER, http://genome.sph.umich.edu/wiki/RAREMETALWORKER
RVTEST, http://zhanxw.github.io/rvtests/
Extended Data
Extended Data Figure 1. 
Flowchart of the GIANT ExomeChip height study design.
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Extended Data Figure 2. 
Height ExomeChip association results. (A) Quantile-quantile plot of ExomeChip variants 
and their association to adult height under an additive genetic model in individuals of 
European ancestry. We stratified results based on allele frequency. (B) Manhattan plot of all 
ExomeChip variants and their association to adult height under an additive genetic model in 
individuals of European ancestry with a focus on the 553 independent SNPs, of which 469 
have MAF>5% (grey), 55 have MAF between 1 and 5% (green), and 29 have MAF<1% 
(blue). (C) Linkage disequilibrium (LD) score regression analysis for the height association 
results in European-ancestry studies. In the plot, each point represents an LD Score quantile, 
where the x-axis of the point is the mean LD Score of variants in that quantile and the y-axis 
is the mean χ2 statistic of variants in that quantile. The LD Score regression slope of the 
black line is calculated based on Equation 1 in Bulik-Sullivan et al.30 which is estimated 
upwards due to the small number of common variants (N=15,848) and the design of the 
ExomeChip. The LD score regression intercept is 1.4, the λGC is 2.7, the mean χ2 is 7.0, 
and the ratio statistic of (intercept -1) / (mean χ2 -1) is 0.067 (standard error=0.012). (D) 
Scatter plot comparison of the effect sizes for all variants that reached significance in the 
European-ancestry discovery results (N=381,625) and results including only studies with 
sample sizes >5000 individuals (N=241,453).
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Extended Data Figure 3. 
Height ExomeChip association results in African-ancestry populations. Among the all-
ancestry results, we found eight variants for which the genetic association with height is 
mostly driven by individuals of African ancestry. The minor allele frequency of these 
variants is <1% (or monomorphic) in all ancestries except African-ancestry individuals. In 
individuals of African ancestry, the variants had allele frequencies between 9 and 40%.
Extended Data Figure 4. 
Concordance between direct conditional effect sizes using UK Biobank (x-axis) and 
conditional analysis performed using a combination of imputation-based methodology and 
approximate conditional analysis (SSimp, y-axis). The Pearson's correlation coefficient is 
r=0.85. The dashed line indicates the identity line. The 95% confidence interval is indicated 
in both directions. Red, SNPs with Pcond>0.05 in the UK Biobank; Green, SNPs with 
Pcond≤0.05 in the UK Biobank.
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Extended Data Figure 5. 
Heritability estimated for all known height variants in the first release of the UK Biobank 
dataset. (A) We observed a weak but significant positive trend between minor allele 
frequency (MAF) and heritability explained (P=0.012). (B) Average heritability explained 
per variant when stratifying the analyses by allele frequency or genomic annotation. For 
heritability estimations in UKBB, variants were pruned to r2< 0.2 in the 1000 Genomes 
Project data set, and the heritability figures are based on h2=80% for height.
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Extended Data Figure 6. 
Comparison of DEPICT gene set enrichment results based on coding variation from 
ExomeChip (EC) or non-coding variation from genome-wide association study data 
(GWAS). The x-axis indicates the P-value for enrichment of a given gene set using DEPICT 
adapted for EC data, where the input to DEPICT is the genes implicated by coding EC 
variants that are independent of known GWAS signals. The y-axis indicates the P-value for 
gene set enrichment using DEPICT, using as input the GWAS loci that do not overlap the 
coding signals. Each point represents a meta-gene set, and the best P-value for any gene set 
within the meta-gene set is shown. Only significant (false discovery rate < 0.01) gene set 
enrichment results are plotted. Colors correspond to whether the meta-gene set was 
significant for EC only (blue), GWAS only (green), both but more significant for EC 
(purple), or both but more significant for GWAS (orange), and the most significant gene sets 
within each category are labeled. A line is drawn at x = y for ease of comparison.
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Extended Data Figure 7. 
Heat map showing entire DEPICT gene set enrichment results (analogous to Fig. 2 in the 
main text). For any given square, the color indicates how strongly the corresponding gene 
(shown on the x-axis) is predicted to belong to the reconstituted gene set (y-axis). This value 
is based on the gene's Z-score for gene set inclusion in DEPICT's reconstituted gene sets, 
where red indicates a higher Z-score and blue indicates a lower one. The proteoglycan 
binding pathway was uniquely implicated by coding variants (as opposed to common 
variants) by both DEPICT and the Pascal method. To visually reduce redundancy and 
increase clarity, we chose one representative “meta-gene set” for each group of highly 
correlated gene sets based on affinity propagation clustering (see Methods and 
Supplementary Information). Heat map intensity and DEPICT p-values correspond to the 
most significantly enriched gene set within the meta-gene set; meta-gene sets are listed with 
their database source. Annotations for the genes indicate whether the gene has OMIM 
annotation as underlying a disorder of skeletal growth (black and grey) and the minor allele 
frequency of the significant EC variant (shades of blue; if multiple variants, the lowest-
frequency variant was kept). Annotations for the gene sets indicate if the gene set was also 
found significant for EC by the Pascal method (yellow and grey) and if the gene set was 
found significant by DEPICT for EC only or for both EC and GWAS (purple and green). 
Abbreviations: GO: Gene Ontology; KEGG: Kyoto encyclopedia of genes and genomes; 
MP: mouse phenotype in the Mouse Genetics Initiative; PPI: protein-protein interaction in 
the InWeb database.
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Extended Data Figure 8. 
Heatmaps showing associations of the height variants to other complex traits; −log10(P-
values) are oriented with beta effect direction for the alternate allele, white are missing 
values, yellow are non-significant (P>0.05), green to blue shading for hits with positive beta 
in the other trait and P-values between 0.05 and <2×10-7 and, orange to red shading for hits 
with negative beta in the other trait and P-values between 0.05 to <2×10-7. Short and tall 
labels are given for the minor alleles. Clustering is done by the complete linkage method 
with Euclidean distance measure for the loci. Clusters highlight SNPs that are more 
significantly associated with the same set of traits. (A) Variants for which the minor allele is 
the height-decreasing allele. (B) Variants for which the minor allele is the height-increasing 
allele.
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Figure 1. 
Variants with a larger effect size on height variation tend to be rarer. We observed an inverse 
relationship between the effect size (from the combined “discovery+validation” analysis, in 
cm on the y-axis) and the minor allele frequency (MAF) for the height variants (x-axis, from 
0 to 50%). We included in this figure the 606 height variants with P<2×10-7.
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Figure 2. 
Heat map showing subset of DEPICT gene set enrichment results. The full heat map is 
available as Extended Data Fig. 7. For any given square, the color indicates how strongly the 
corresponding gene (shown on the x-axis) is predicted to belong to the reconstituted gene set 
(y-axis). This value is based on the gene's Z-score for gene set inclusion in DEPICT's 
reconstituted gene sets, where red indicates a higher Z-score and blue indicates a lower one. 
The proteogly can binding pathway (bold) was uniquely implicated by coding variants by 
DEPICT and PASCAL. To visually reduce redundancy and increase clarity, we chose one 
representative “meta-gene set” for each group of highly correlated gene sets based on 
affinity propagation clustering (Supplementary Information). Heat map intensity and 
DEPICT P-values correspond to the most significantly enriched gene set within the meta-
gene set; meta-gene sets are listed with their database source. Annotations for the genes 
indicate whether the gene has OMIM annotation as underlying a disorder of skeletal growth 
(black and grey) and the minor allele frequency of the significant ExomeChip (EC) variant 
(shades of blue; if multiple variants, the lowest-frequency variant was kept). Annotations for 
the gene sets indicate if the gene set was also found significant for EC by PASCAL (yellow 
and grey) and if the gene set was found significant by DEPICT for EC only or for both EC 
and GWAS (purple and green). Abbreviations: GO: Gene Ontology; MP: mouse phenotype 
in the Mouse Genetics Initiative; PPI: protein-protein interaction in the In Web database.
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Figure 3. 
STC2 mutants p.Arg44Leu (R44L) and p.Met86Ile (M86I) show compromised proteolytic 
inhibition of PAPP-A. (A) Schematic representation of the role of STC2 in IGF-1 signaling. 
Partial inactivation of STC2 by height-associated DNA sequence variation could increase 
bioactive IGF-1 through reduced inhibition of PAPP-A. (B) Western blot analysis of 
recombinant STC2 wild-type and variants R44L and M86I. (C) Covalent complex formation 
between PAPP-A and STC2 wild-type or variants R44L and M86I. Separately synthesized 
proteins were analyzed by PAPP-A Western blotting following incubation for 8 h. In the 
absence of STC2 (Mock lane), PAPP-A appears as a single 400 kDa band (*). Following 
incubation with wild-type STC2, the majority of PAPP-A is present as the approximately 
500 kDa covalent PAPP-A:STC2 complex (#), in which PAPP-A is devoid of proteolytic 
activity towards IGFBP-4. Under similar conditions, incubation with variants R44L or M86I 
appeared to cause less covalent complex formation with PAPP-A. The gels are representative 
of at least three independent experiments. (D) PAPP-A proteolytic cleavage of IGFBP-4 
following incubation with wild-type STC2 or variants for 1-24 h. Wild-type STC2 causes 
reduction in PAPP-A activity, with complete inhibition of activity following 24 h incubation. 
Both STC2 variants show increased IGFBP-4 cleavage (i.e. less inhibition) for all time 
points analyzed. Mean and standard deviations of three independent experiments are shown. 
One-way repeated measures analysis of variance followed by Dunnett's post-test showed 
significant differences between STC2 wild-type and variants R44L (P<0.001) and M86I 
(P<0.01).
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